Mediwound is a biopharmaceutical company focused on developing, manufacturing and commercializing therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other wounds, connective tissue disorders and other indications. Co.'s primary biopharmaceutical product, NexoBrid, has received marketing authorization for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. Co.'s second product candidate, EscharEx, is a topical biological product being developed for debridement of chronic and other wounds. The MDWD stock yearly return is shown above.
The yearly return on the MDWD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MDWD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|